ArticleClinical diabetes and endocrinology2024

A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV).

Prabhat K Agarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.